August 22, 2006 – The FDA canceled the Advisory Committee meeting on Wyeth’s drug for major depressive order, which Wyeth took as a signal of approval; Protalix, an Israeli biotech with high-powered connections, will execute a reverse merger with Orthodontix; Wyeth and Progenics began a test of their drug for opioid-induced constipation; GenVec will start a Phase I test of its HIV vaccine in HIV-infected patients; Myriad Genetics completed enrolment in its Phase III trial of Flurizan for Alzheimer’s; Medarex will partner with GenPat77 in a drug discovery deal; and Novartis will collaborate with Entelos. The Centient Biotech 200™ fell 16 points to 3677, a loss of .44%. More details...
